Literature DB >> 6296695

Evidence that the insulin secretagogue, beta-cell-tropin, is ACTH22-39.

A Beloff-Chain, J Morton, S Dunmore, G W Taylor, H R Morris.   

Abstract

The pituitary neurointermediate lobe of genetically obese (ob/ob) mice contains a hormone which stimulates insulin release and which cross-reacts with a -COOH-terminal ACTH antiserum, suggesting that it is related to corticotropin-like intermediate lobe peptide (CLIP), the 18-39 fragment of ACTH. The hormone, which we have called beta-cell-tropin, has been shown to be present in the plasma of the ob/ob mouse and to potentiate glucose induced insulin secretion. We have now shown that ACTH22-39 prepared by tryptic digestion of human synthetic CLIP behaves similarly on Biogel chromatography and on reverse-phase HPLC to the naturally occurring beta-cell-tropin. Furthermore, beta-cell-tropin and ACTH22-39 have indistinguishable antigenic and insulin releasing properties.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6296695     DOI: 10.1038/301255a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  11 in total

Review 1.  The renaissance of corticotropin therapy in proteinuric nephropathies.

Authors:  Rujun Gong
Journal:  Nat Rev Nephrol       Date:  2011-12-06       Impact factor: 28.314

2.  Physiological concentrations of oxytocin powerfully stimulate insulin secretionin vitro.

Authors:  E Bobbioni-Harsch; S Frütiger; G Hughes; M Panico; A Etienne; F Zappacosta; H R Morris; B Jeanrenaud
Journal:  Endocrine       Date:  1995-01       Impact factor: 3.633

3.  Hypothalamic control of lipid metabolism.

Authors:  P Schwandt
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

4.  alpha-Melanocyte-stimulating-hormone precursors in the pig pituitary.

Authors:  M Fenger
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

Review 5.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

6.  The effects of structural modifications on the insulin-releasing activity of beta-cell-tropin.

Authors:  S J Dunmore; M Panico; A T Etienne; H R Morris; A Beloff-Chain
Journal:  Biochem J       Date:  1987-06-15       Impact factor: 3.857

7.  Beta-cell damage in diabetic insulitis: are we approaching a solution?

Authors:  G F Bottazzo
Journal:  Diabetologia       Date:  1984-04       Impact factor: 10.122

8.  Effect of corticotropin-like intermediate lobe peptide on pancreatic exocrine function in isolated rat pancreatic lobules.

Authors:  J B Marshall; L P Kapcala; L D Manning; A J McCullough
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

9.  Low-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot study.

Authors:  Paolo Lorusso; Anna Bottai; Emanuela Mangione; Maurizio Innocenti; Adamasco Cupisti; Maria Francesca Egidi
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-02-05

10.  Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.

Authors:  Anne-Els van de Logt; Charles H Beerenhout; Hans S Brink; Jos J van de Kerkhof; Jack F Wetzels; Julia M Hofstra
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.